Assignee
ATROGI AB
SE·11 granted patents·14 pending applications·42 citations·filing 2013–2024
Top patents by PatentIndex Score
25 records- 0194US11357757B2Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemiaATROGI AB·Filed 2018·Granted Jun 14, 2022·6 cites·8 claims
- 0293US10288602B2Screening method, a kit, a method of treatment and a compound for use in a method of treatementATROGI AB·Filed 2017·Granted May 14, 2019·7 cites·2 claims
- 0389US9784726B2Screening method, a kit, a method of treatment and a compound for use in a method of treatmentATROGI AB·Filed 2014·Granted Oct 10, 2017·8 cites·8 claims
- 0489US9657348B2Method of screening compounds for the treatment of diabetesATROGI AB·Filed 2014·Granted May 23, 2017·9 cites·11 claims
- 0588US9891212B2Screening method, a kit, a method of treatment and a compound for use in a method of treatmentATROGI AB·Filed 2013·Granted Feb 13, 2018·8 cites·10 claims
- 0680US11648216B2Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemiaATROGI AB·Filed 2018·Granted May 16, 2023·1 cites·5 claims
- 0780US11427539B2Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemiaATROGI AB·Filed 2018·Granted Aug 30, 2022·3 cites·16 claims
- 0880US2024398770A1Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemiaATROGI AB·Filed 2024·Application pending·0 cites
- 0976US12036210B2Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemiaATROGI AB·Filed 2022·Granted Jul 16, 2024·0 cites·10 claims
- 1068US12280023B2Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemiaATROGI AB·Filed 2023·Granted Apr 22, 2025·0 cites·28 claims
- 1168US2021338603A1Combinations of adrenergic receptor agonists for the treatment of type 2 diabetesATROGI AB·Filed 2021·Application pending·0 cites
- 1264US2020315993A1Combinations of adrenergic receptor agonists for the treatment of type 2 diabetesATROGI AB·Filed 2020·Application pending·0 cites
- 1364US2025042856A1Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2ATROGI AB·Filed 2022·Application pending·0 cites
- 1463US2025223296A1Hydroxymethyl azabicyclo[2.2.1]heptanes and medical uses thereofATROGI AB·Filed 2023·Application pending·0 cites
- 1563US2025262170A1Combinations of beta 2-adrenergic receptor agonists and beta 3-adrenergic receptor agonists, and medical uses thereofATROGI AB·Filed 2023·Application pending·0 cites
- 1660US2024391871A1Substituted hydroxymethyl pyrrolidines and medical uses thereofATROGI AB·Filed 2022·Application pending·0 cites
- 1760US2024390298A1Cyclohexyl beta-hydroxy alkyl amines and medical uses thereofATROGI AB·Filed 2022·Application pending·0 cites
- 1856US2023365572A1Hydroxylbenzyl azabicyclo[2.2.1]heptan-1-ane drivatives and medical uses thereofATROGI AB·Filed 2021·Application pending·0 cites
- 1955US2024010620A1Arylazabicyclo[2.1.1]hexylmethanols derivatives and medical uses thereofATROGI AB·Filed 2021·Application pending·0 cites
- 2052US2019314301A1Combinations of adrenergic receptor agonists for the treatment of type 2 diabetesATROGI AB·Filed 2017·Application pending·0 cites
- 2151US12378216B2Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemiaATROGI AB·Filed 2020·Granted Aug 5, 2025·0 cites·7 claims
- 2250US2022152004A1Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemiaATROGI AB·Filed 2020·Application pending·0 cites
- 2349US11793774B2Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemiaATROGI AB·Filed 2018·Granted Oct 24, 2023·0 cites·19 claims
- 2448US2017153225A1A method of screening for a compound capable of stimulating glucose transport into brown and/or brite adipocytes of a mammal, a kit for use in such a methodATROGI AB·Filed 2014·Application pending·0 cites
- 2539US2019119196A1Compounds for the treatment of hyperglycaemiaATROGI AB·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →